Who is sponsoring NCT05417633?

NCT05417633 is sponsored by Somich, s.r.o..

What drugs are being tested in NCT05417633?

Interventions in NCT05417633: intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland).

What condition does NCT05417633 study?

NCT05417633 studies Cataract Senile, Presbyopia.

Is NCT05417633 still recruiting?

NCT05417633 is currently status unknown. Last updated 14 June 2022.

Last reviewed 2022-06-14 · How we verify

NCT05417633: EMV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RayOne EMV Mini-monovision - Efficiency and Safety of 3 Grades of Mini-monovision

Status unknown NA Last updated 14 June 2022

What this trial tests

NA trial testing intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland) in Cataract Senile in 60 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2022

21 March 2023

Quick facts

Lead sponsor	Somich, s.r.o.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 January 2022
Primary completion	31 December 2022
Estimated completion	21 March 2023
Sites	1 location across Czechia

Drugs / interventions tested

intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)

Conditions studied

Cataract Senile — all drugs for Cataract Senile →
Presbyopia — all drugs for Presbyopia →

Sponsor

Somich, s.r.o.

Who can join

50 and older, any sex, with Cataract Senile or Presbyopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim:To determine the effectiveness and subjective satisfaction of patients with bilateral cataract surgery and implantation of intraocular lens (IOL) RayOne EMV with enhanced optic, using different degrees of mini-monovision (up to 0.74, between 0.75 -1.24 and 1.25-1.75). To compare individual groups between themselves . In particular, we would like to compare the independence of spectacle correction when looking into the distance, at medium distance and at reading distance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Human retinal secretome: A cross-link between mesenchymal and retinal cells.
Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665

Verify or expand the search:

Other recruiting trials for Cataract Senile

Currently open trials in the same condition.

NCT04570579 — Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05417633 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Somich, s.r.o.
Last refreshed: 14 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing